NovaBay Pharmaceuticals Inc
XBER:B9P
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
N
|
NovaBay Pharmaceuticals Inc
XBER:B9P
|
480.5k EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
250.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
NovaBay Pharmaceuticals Inc
Glance View
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 29 full-time employees. The company went IPO on 2007-10-26. The firm develops and sells scientifically created and clinically proven eyecare and skincare products. Its product, Avenova Antimicrobial Lid & Lash Solution is used for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution. Its trademarks include Avenova, CelleRx, PhaseOne, NeutroPhase, DERMAdoctor, Kakadu C, AINT Misbehavin, KP Duty, and depictions of Dr. Audrey Kunin. Avenova Spray has broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The Company, through its subsidiary DERMAdoctor, LLC, offers approximately 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration, and keratosis pilaris.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for NovaBay Pharmaceuticals Inc is 54.5%, which is in line with its 3-year median of 54.5%.
Over the last 3 years, NovaBay Pharmaceuticals Inc’s Gross Margin has decreased from 60.9% to 54.5%. During this period, it reached a low of 53.6% on Dec 31, 2023 and a high of 70.7% on Dec 31, 2021.
